Search

Your search keyword '"Yan, Yingjun"' showing total 42 results
Start Over Author "Yan, Yingjun"
42 results on '"Yan, Yingjun"'

2. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation

Author

Brown, Benjamin P, Zhang, Yun-Kai, Westover, David, Yan, Yingjun, Qiao, Huan, Huang, Vincent, Du, Zhenfang, Smith, Jarrod A, Ross, Jeffrey S, Miller, Vincent A, Ali, Siraj, Bazhenova, Lyudmila, Schrock, Alexa B, Meiler, Jens, and Lovly, Christine M

Subjects
Genetics, Cancer, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Acrylamides, Alleles, Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, ErbB Receptors, Exons, Gene Expression Profiling, Humans, Lung Neoplasms, Models, Molecular, Mutation, Protein Binding, Protein Kinase Inhibitors, Structure-Activity Relationship, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer. Despite the development of highly selective third-generation inhibitors, acquired resistance remains a significant clinical challenge. Recently, we and others have identified a novel osimertinib resistance mutation, G724S, which was not predicted in in vitro screens. Here, we investigate how G724S confers resistance to osimertinib.Experimental Design: We combine structure-based predictive modeling of G724S in combination with the 2 most common EGFR-activating mutations, exon 19 deletion (Ex19Del) and L858R, with in vitro drug-response models and patient genomic profiling.ResultsOur simulations suggest that the G724S mutation selectively reduces osimertinib-binding affinity in the context of Ex19Del. Consistent with our simulations, cell lines transduced with Ex19Del/G724S demonstrate resistance to osimertinib, whereas cells transduced with L858R/G724S are sensitive to osimertinib. Subsequent clinical genomic profiling data further suggest G724S occurs with Ex19Del but not L858R. Furthermore, we demonstrate that Ex19Del/G724S retains sensitivity to afatinib, but not to erlotinib, suggesting a possible therapy for patients at the time of disease relapse.ConclusionsAltogether, these data suggest that G724S is an allele-specific resistance mutation emerging in the context of Ex19Del but not L858R. Our results fundamentally reframe the problem of targeted therapy resistance from one focused on the "drug-resistance mutation" pair to one focused on the "activating mutation-drug-resistance mutation" trio. This has broad implications across clinical oncology.

Published
2019

5. Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease

Author

Iams, Wade T., Kopparapu, Prasad R., Yan, Yingjun, Muterspaugh, Anel, Zhao, Zhiguo, Chen, Heidi, Cann, Christopher, York, Sally, Horn, Leora, Ancell, Kristin, Wyman, Kenneth, Bertucci, Caterina, Shaffer, Tristan, Hodsdon, Lauren A., Garg, Kavita, Hosseini, Seyed Ali, Lim, Lee P., and Lovly, Christine M.

Published
2020
Full Text
View/download PDF

6. Structure–function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting

Author

Du, Zhenfang, Brown, Benjamin P., Kim, Soyeon, Ferguson, Donna, Pavlick, Dean C., Jayakumaran, Gowtham, Benayed, Ryma, Gallant, Jean-Nicolas, Zhang, Yun-Kai, Yan, Yingjun, Red-Brewer, Monica, Ali, Siraj M., Schrock, Alexa B., Zehir, Ahmet, Ladanyi, Marc, Smith, Adam W., Meiler, Jens, and Lovly, Christine M.

Published
2021
Full Text
View/download PDF

8. Data from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Author

Konduri, Kartik, primary, Gallant, Jean-Nicolas, primary, Chae, Young Kwang, primary, Giles, Francis J., primary, Gitlitz, Barbara J., primary, Gowen, Kyle, primary, Ichihara, Eiki, primary, Owonikoko, Taofeek K., primary, Peddareddigari, Vijay, primary, Ramalingam, Suresh S., primary, Reddy, Satyanarayan K., primary, Eaby-Sandy, Beth, primary, Vavalà, Tiziana, primary, Whiteley, Andrew, primary, Chen, Heidi, primary, Yan, Yingjun, primary, Sheehan, Jonathan H., primary, Meiler, Jens, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ali, Siraj M., primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figures S1 - S10 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Author

Konduri, Kartik, primary, Gallant, Jean-Nicolas, primary, Chae, Young Kwang, primary, Giles, Francis J., primary, Gitlitz, Barbara J., primary, Gowen, Kyle, primary, Ichihara, Eiki, primary, Owonikoko, Taofeek K., primary, Peddareddigari, Vijay, primary, Ramalingam, Suresh S., primary, Reddy, Satyanarayan K., primary, Eaby-Sandy, Beth, primary, Vavalà, Tiziana, primary, Whiteley, Andrew, primary, Chen, Heidi, primary, Yan, Yingjun, primary, Sheehan, Jonathan H., primary, Meiler, Jens, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ali, Siraj M., primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Methods, Figure Legends, Table Legends from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Author

Konduri, Kartik, primary, Gallant, Jean-Nicolas, primary, Chae, Young Kwang, primary, Giles, Francis J., primary, Gitlitz, Barbara J., primary, Gowen, Kyle, primary, Ichihara, Eiki, primary, Owonikoko, Taofeek K., primary, Peddareddigari, Vijay, primary, Ramalingam, Suresh S., primary, Reddy, Satyanarayan K., primary, Eaby-Sandy, Beth, primary, Vavalà, Tiziana, primary, Whiteley, Andrew, primary, Chen, Heidi, primary, Yan, Yingjun, primary, Sheehan, Jonathan H., primary, Meiler, Jens, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ali, Siraj M., primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Tables S1 - S3 from EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Author

Konduri, Kartik, primary, Gallant, Jean-Nicolas, primary, Chae, Young Kwang, primary, Giles, Francis J., primary, Gitlitz, Barbara J., primary, Gowen, Kyle, primary, Ichihara, Eiki, primary, Owonikoko, Taofeek K., primary, Peddareddigari, Vijay, primary, Ramalingam, Suresh S., primary, Reddy, Satyanarayan K., primary, Eaby-Sandy, Beth, primary, Vavalà, Tiziana, primary, Whiteley, Andrew, primary, Chen, Heidi, primary, Yan, Yingjun, primary, Sheehan, Jonathan H., primary, Meiler, Jens, primary, Morosini, Deborah, primary, Ross, Jeffrey S., primary, Stephens, Philip J., primary, Miller, Vincent A., primary, Ali, Siraj M., primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

12. Data from SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Author

Ichihara, Eiki, primary, Westover, David, primary, Meador, Catherine B., primary, Yan, Yingjun, primary, Bauer, Joshua A., primary, Lu, Pengcheng, primary, Ye, Fei, primary, Kulick, Amanda, primary, de Stanchina, Elisa, primary, McEwen, Robert, primary, Ladanyi, Marc, primary, Cross, Darren, primary, Pao, William, primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figures 1 through 9 from SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Author

Ichihara, Eiki, primary, Westover, David, primary, Meador, Catherine B., primary, Yan, Yingjun, primary, Bauer, Joshua A., primary, Lu, Pengcheng, primary, Ye, Fei, primary, Kulick, Amanda, primary, de Stanchina, Elisa, primary, McEwen, Robert, primary, Ladanyi, Marc, primary, Cross, Darren, primary, Pao, William, primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legends and Supplementary Tables 1 and 2 from SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Author

Ichihara, Eiki, primary, Westover, David, primary, Meador, Catherine B., primary, Yan, Yingjun, primary, Bauer, Joshua A., primary, Lu, Pengcheng, primary, Ye, Fei, primary, Kulick, Amanda, primary, de Stanchina, Elisa, primary, McEwen, Robert, primary, Ladanyi, Marc, primary, Cross, Darren, primary, Pao, William, primary, and Lovly, Christine M., primary

Published
2023
Full Text
View/download PDF

18. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer

Author

Brown, Benjamin P., primary, Zhang, Yun-Kai, additional, Kim, Soyeon, additional, Finneran, Patrick, additional, Yan, Yingjun, additional, Du, Zhenfang, additional, Kim, Jiyoon, additional, Hartzler, Abigail Leigh, additional, LeNoue-Newton, Michele L., additional, Smith, Adam W., additional, Meiler, Jens, additional, and Lovly, Christine M., additional

Published
2022
Full Text
View/download PDF

20. Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC

Author

Smith, Jarrod T., Balar, Aneri, Lakhani, Dhairya A., Kluwe, Christien, Zhao, Zhiguo, Kopparapu, Prasad, Almodovar, Karinna, Muterspaugh, Anel, Yan, Yingjun, York, Sally, Horn, Leora, Antic, Sanja, Bertucci, Caterina, Shaffer, Tristan, Hodsdon, Lauren, Garg, Kavita, Hosseini, Seyed Ali, Lim, Lee, Osmundson, Evan, Massion, Pierre P., Lovly, Christine M., and Iams, Wade

Published
2021
Full Text
View/download PDF

23. Abstract 715: Circulating tumor DNA as a potential biomarker of radiographic tumor burden in small cell lung cancer

Author

Smith, Jarrod T., primary, Balar, Aneri, additional, Lakhani, Dhairya A., additional, Kluwe, Christien, additional, Zhao, Zhiguo, additional, Kopparapu, Prasad, additional, Almodovar, Karinna, additional, Muterspaugh, Anel, additional, Yan, Yingjun, additional, York, Sally, additional, Horn, Leora, additional, Antic, Sanja, additional, Bertucci, Caterina, additional, Shaffer, Tristan, additional, Hodsdon, Lauren, additional, Garg, Kavita, additional, Hosseini, Seyed Ali, additional, Lim, Lee, additional, Osmundson, Evan, additional, Massion, Pierre, additional, Lovly, Christine, additional, and Iams, Wade, additional

Published
2020
Full Text
View/download PDF

24. Abstract B20: Prolonged time to clearance of circulating-tumor DNA from patients with limited-stage small-cell lung cancer is associated with inferior progression-free and overall survival

Author

Cann, Christopher, primary, Kopparapu, Prasad, additional, Yan, Yingjun, additional, Muterspaugh, Anel, additional, Chen, Heidi, additional, Zhao, Zhiguo, additional, York, Sally, additional, Horn, Leora, additional, Ancell, Kristen, additional, Wyman, Kenneth, additional, Bertucci, Caterina, additional, Shaffer, Tristan, additional, Hodson, Lauren, additional, Garg, Kavita, additional, Hosseini, Seyed Ali, additional, Lim, Lee, additional, Lovly, Christine M., additional, and Iams, Wade, additional

Published
2020
Full Text
View/download PDF

28. Abstract 930: On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation

Author

Zhang, Yunkai, primary, Brown, Benjamin P., additional, Westover, David, additional, Yan, Yingjun, additional, Qiao, Huan, additional, Huang, Vincent, additional, Du, Zhenfang, additional, Smith, Jarrod A., additional, Ross, Jeffrey S., additional, Miller, Vincent A., additional, Ali, Siraj, additional, Bazhenova, Lyudmila, additional, Schrock, Alexa B., additional, Meiler, Jens, additional, and Lovly, Christine M., additional

Published
2019
Full Text
View/download PDF

32. SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Author

Ichihara, Eiki, primary, Westover, David, additional, Meador, Catherine B., additional, Yan, Yingjun, additional, Bauer, Joshua A., additional, Lu, Pengcheng, additional, Ye, Fei, additional, Kulick, Amanda, additional, de Stanchina, Elisa, additional, McEwen, Robert, additional, Ladanyi, Marc, additional, Cross, Darren, additional, Pao, William, additional, and Lovly, Christine M., additional

Published
2017
Full Text
View/download PDF

34. EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

Author

Konduri, Kartik, primary, Gallant, Jean-Nicolas, additional, Chae, Young Kwang, additional, Giles, Francis J., additional, Gitlitz, Barbara J., additional, Gowen, Kyle, additional, Ichihara, Eiki, additional, Owonikoko, Taofeek K., additional, Peddareddigari, Vijay, additional, Ramalingam, Suresh S., additional, Reddy, Satyanarayan K., additional, Eaby-Sandy, Beth, additional, Vavalà, Tiziana, additional, Whiteley, Andrew, additional, Chen, Heidi, additional, Yan, Yingjun, additional, Sheehan, Jonathan H., additional, Meiler, Jens, additional, Morosini, Deborah, additional, Ross, Jeffrey S., additional, Stephens, Philip J., additional, Miller, Vincent A., additional, Ali, Siraj M., additional, and Lovly, Christine M., additional

Published
2016
Full Text
View/download PDF

35. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer

Author

Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretic, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansen, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Juergen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, Pao, William, Lovly, Christine M., McDonald, Nerina T., Chen, Heidi, Ortiz-Cuaran, Sandra, Heukamp, Lukas C., Yan, Yingjun, Florin, Alexandra, Ozretic, Luka, Lim, Diana, Wang, Lu, Chen, Zhao, Chen, Xi, Lu, Pengcheng, Paik, Paul K., Shen, Ronglai, Jin, Hailing, Buettner, Reinhard, Ansen, Sascha, Perner, Sven, Brockmann, Michael, Bos, Marc, Wolf, Juergen, Gardizi, Masyar, Wright, Gavin M., Solomon, Benjamin, Russell, Prudence A., Rogers, Toni-Maree, Suehara, Yoshiyuki, Red-Brewer, Monica, Tieu, Rudy, de Stanchina, Elisa, Wang, Qingguo, Zhao, Zhongming, Johnson, David H., Horn, Leora, Wong, Kwok-Kin, Thomas, Roman K., Ladanyi, Marc, and Pao, William

Abstract

Crizotinib, a selective tyrosine kinase inhibitor (TKI), shows marked activity in patients whose lung cancers harbor fusions in the gene encoding anaplastic lymphoma receptor tyrosine kinase (ALK), but its efficacy is limited by variable primary responses and acquired resistance. In work arising from the clinical observation of a patient with ALKfusion-positive lung cancer who had an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody, we define a therapeutic synergism between ALK and IGF-1R inhibitors. Similar to IGF-1R, ALK fusion proteins bind to the adaptor insulin receptor substrate 1 (IRS-1), and IRS-1 knockdown enhances the antitumor effects of ALK inhibitors. In models of ALK TKI resistance, the IGF-1R pathway is activated, and combined ALK and IGF-1R inhibition improves therapeutic efficacy. Consistent with this finding, the levels of IGF-1R and IRS-1 are increased in biopsy samples from patients progressing on crizotinib monotherapy. Collectively these data support a role for the IGF-1R-IRS-1 pathway in both ALK TKI-sensitive and ALK TKI-resistant states and provide a biological rationale for further clinical development of dual ALK and IGF-1R inhibitors.

Published
2014

36. Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

Author

Lovly, Christine M, primary, McDonald, Nerina T, additional, Chen, Heidi, additional, Ortiz-Cuaran, Sandra, additional, Heukamp, Lukas C, additional, Yan, Yingjun, additional, Florin, Alexandra, additional, Ozretić, Luka, additional, Lim, Diana, additional, Wang, Lu, additional, Chen, Zhao, additional, Chen, Xi, additional, Lu, Pengcheng, additional, Paik, Paul K, additional, Shen, Ronglai, additional, Jin, Hailing, additional, Buettner, Reinhard, additional, Ansén, Sascha, additional, Perner, Sven, additional, Brockmann, Michael, additional, Bos, Marc, additional, Wolf, Jürgen, additional, Gardizi, Masyar, additional, Wright, Gavin M, additional, Solomon, Benjamin, additional, Russell, Prudence A, additional, Rogers, Toni-Maree, additional, Suehara, Yoshiyuki, additional, Red-Brewer, Monica, additional, Tieu, Rudy, additional, de Stanchina, Elisa, additional, Wang, Qingguo, additional, Zhao, Zhongming, additional, Johnson, David H, additional, Horn, Leora, additional, Wong, Kwok-Kin, additional, Thomas, Roman K, additional, Ladanyi, Marc, additional, and Pao, William, additional

Published
2014
Full Text
View/download PDF

37. A Microfluidic-Enabled Mechanical Microcompressor for the Immobilization of Live Single- and Multi-Cellular Specimens

Author

Yan, Yingjun, primary, Jiang, Liwei, additional, Aufderheide, Karl J., additional, Wright, Gus A., additional, Terekhov, Alexander, additional, Costa, Lino, additional, Qin, Kevin, additional, McCleery, W. Tyler, additional, Fellenstein, John J., additional, Ustione, Alessandro, additional, Robertson, J. Brian, additional, Johnson, Carl Hirschie, additional, Piston, David W., additional, Hutson, M. Shane, additional, Wikswo, John P., additional, Hofmeister, William, additional, and Janetopoulos, Chris, additional

Published
2014
Full Text
View/download PDF

39. Improved Identification of Yeast Species Directly from Positive Blood Culture Media by Combining Sepsityper Specimen Processing and Microflex Analysis with the Matrix-Assisted Laser Desorption Ionization Biotyper System

Author

Yan, Yingjun, primary, He, Ying, additional, Maier, Thomas, additional, Quinn, Criziel, additional, Shi, Gongyi, additional, Li, Haijing, additional, Stratton, Charles W., additional, Kostrzewa, Markus, additional, and Tang, Yi-Wei, additional

Published
2011
Full Text
View/download PDF

40. A Novel Pseudomonas aeruginosaStrain with an oprDMutation in Relation to a Nosocomial Respiratory Infection Outbreak in an Intensive Care Unit

Author

Yan, Yingjun, Yao, Xiangyu, Li, Haijing, Zhou, Zhonghua, Huang, Wenfang, Stratton, Charles W., Lu, Chung-Dar, and Tang, Yi-Wei

Abstract

ABSTRACTSeven imipenem-resistant Pseudomonas aeruginosaisolates were recovered from the sputum samples of pneumonia patients in southwestern China. They had identical antibiotic resistance patterns and indistinguishable pulsed-field gel electrophoresis profiles. Nucleotide sequence analysis revealed a 4-bp (AGTC) insertion in the oprDgene, resulting in a frameshift in the cognate open reading frame. These isolates became imipenem susceptible when the chromosomal oprDlesion was complemented, indicating that the 4-bp insertion in the oprDgene resulted in imipenem resistance.

Published
2014
Full Text
View/download PDF

41. A novel Pseudomonas aeruginosa strain with an oprD mutation in relation to a nosocomial respiratory infection outbreak in an intensive care unit.

Author

Yan Y, Yao X, Li H, Zhou Z, Huang W, Stratton CW, Lu CD, and Tang YW

Subjects
Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents pharmacology, China epidemiology, DNA, Bacterial chemistry, DNA, Bacterial genetics, Electrophoresis, Gel, Pulsed-Field, Genetic Complementation Test, Genotype, Humans, Imipenem pharmacology, Intensive Care Units, Male, Microbial Sensitivity Tests, Molecular Sequence Data, Molecular Typing, Mutagenesis, Insertional, Pneumonia, Bacterial epidemiology, Pseudomonas Infections epidemiology, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa isolation & purification, Sequence Analysis, DNA, Sputum microbiology, Disease Outbreaks, Frameshift Mutation, Pneumonia, Bacterial microbiology, Porins genetics, Pseudomonas Infections microbiology, Pseudomonas aeruginosa genetics
Abstract

Seven imipenem-resistant Pseudomonas aeruginosa isolates were recovered from the sputum samples of pneumonia patients in southwestern China. They had identical antibiotic resistance patterns and indistinguishable pulsed-field gel electrophoresis profiles. Nucleotide sequence analysis revealed a 4-bp (AGTC) insertion in the oprD gene, resulting in a frameshift in the cognate open reading frame. These isolates became imipenem susceptible when the chromosomal oprD lesion was complemented, indicating that the 4-bp insertion in the oprD gene resulted in imipenem resistance., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)

Published
2014
Full Text
View/download PDF

42. [Clinical applications of anterolateral thigh flap].

Author

Sun B, Qiao Q, and Yan Y

Subjects
Female, Follow-Up Studies, Humans, Male, Soft Tissue Injuries surgery, Thigh, Fascia transplantation, Skin Transplantation, Surgical Flaps
Abstract

Objective: To discuss different applications of anterolateral thigh flap in repairing large skin-soft tissue defects., Methods: From January 1997 to July 2004, 27 patients with large-complex tissue defects were treated using anterolateral thigh flap. The tissue defect was located at face in 9 cases, at cervix in 4 cases, at lower limbs in 6 cases, at vulvae in 4 cases, at hip in 1 case, at groin in 1 case and at breast tissue in 2 cases. The defect area was from 9 cm X 8 cm to 20 cm X 15 cm and the flap was harvested from 10 cm X 8 cm to 33 cm X 15 cm., Results: Flaps survived in 26 cases after operation, and patients were satisfied with local function and appearance; flap necrosis occurred only in 1 case, and the defect was covered with free skin graft after dress exchanges. Twenty-three cases were followed up from 3 months to 2 years. The appearance and the sense of recipient site were similar to the adjacent tissue. No obvious malformation of the donor site was observed. No local recurrence was found in the 6 cases of malignancy during the follow-up from 6 months to 15 months., Conclusion: Anterolateral thigh skin flap can provide enough tissue to repair large skin-soft tissue defect, and can be used in different ways. So anterolateral femoral skin flap is an ideal flap in repairing large skin-soft tissue defect.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results